ストックスクリーナーアプリを入手
17.55
2.51%
0.43
前日終値:
$17.12
開ける：
$17.64
24時間の取引高:
4.24M
Relative Volume:
2.40
時価総額：
$1.81B
収益：
$71.78M
当期純損益:
$-295.28M
株価収益率:
-5.5543
EPS:
-3.1597
ネットキャッシュフロー:
$-271.85M
1週間 パフォーマンス:
+3.36%
1か月 パフォーマンス:
+13.15%
6か月 パフォーマンス:
-2.55%
1年 パフォーマンス:
+51.03%
1日の値動き範囲:
$16.95
$17.89
1週間の範囲:
$16.50
$18.91
52週間の値動き範囲:
$8.195
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
名前
Nurix Therapeutics Inc
セクター
電話
(415) 660-5320
住所
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
17.55 | 1.81B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-10-21 | 開始されました | Mizuho | Outperform |
| 2025-03-17 | 開始されました | Leerink Partners | Market Perform |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-11 | 開始されました | Jefferies | Buy |
| 2024-09-06 | 再開されました | Robert W. Baird | Outperform |
| 2024-07-31 | 開始されました | Truist | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-03-09 | 開始されました | Barclays | Overweight |
| 2023-02-28 | 開始されました | Oppenheimer | Outperform |
| 2022-10-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-12-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-30 | 再開されました | Piper Sandler | Overweight |
| 2021-04-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-11-19 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
| 2020-08-18 | 開始されました | Needham | Buy |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-18 | 開始されました | Stifel | Buy |
すべてを表示
Nurix Therapeutics Inc (NRIX) 最新ニュース
Nurix Therapeutics Stockanalyst snapshot and weekly review - AD HOC NEWS
Nurix surges 43% on up to $3B cancer drug deal with Roche - MSN
NRIX Maintained by Baird -- Price Target Raised to $33 - GuruFocus
Strength seen in Nurix Therapeutics (NRIX): Can its 6.8% jump turn into more strength? - MSN
Nurix Therapeutics, Inc. $NRIX Position Boosted by Baker BROS. Advisors LP - MarketBeat
Perceptive Advisors LLC Buys 2,139,728 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Elmind Capital LP Takes $8.73 Million Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics, Inc. $NRIX Shares Sold by Commodore Capital LP - MarketBeat
Nurix Therapeutics Inc (NRIX) Institutional Confidence - TradingKey
Nurix Therapeutics Inc (NRIX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nurix Therapeutics Inc (NRIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nurix Therapeutics Inc (NRIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Nurix Therapeutics Inc (NRIX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
General Atlantic L.P. Buys Shares of 4,897,159 Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics Inc (NRIX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nurix Therapeutics Inc (NRIX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nurix Therapeutics Inc (NRIX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Trading the Move, Not the Narrative: (NRIX) Edition - Stock Traders Daily
Nurix Therapeutics (NRIX) Stock Looks Expensive Even With A $31 Analyst Target - Yahoo Finance
Truist is Bullish on Nurix Therapeutics, Inc. (NRIX) - Insider Monkey
Nurix stock delivers 64% return after Fair Value spotted opportunity By Investing.com - Investing.com South Africa
Nurix stock delivers 64% return after Fair Value spotted opportunity - Investing.com
Nurix Therapeutics Inc (NRIX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NRIX Reiterated by Needham -- Price Target Maintained at $34 - GuruFocus
Stifel Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Needham & Company LLC Reaffirms Buy Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Needham Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Nurix, BioNxt Solutions, Zealand Pharma: New Therapies Ignite the Imagination - news.financial
Kymera, Monte Rosa among gainers as Novartis inks deal for molecular glue drugs - MSN
BTIG Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
H.C. Wainwright Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
J.P. Morgan Maintains Nurix Therapeutics(NRIX.US) With Buy Rating - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy - Investing News Network
Nurix (NRIX) presents updated Bexobrutideg data at EHA 2026 - grafa.com
H.C. Wainwright reiterates Nurix stock rating on Roche deal - Investing.com UK
Nurix reports updated clinical data for CLL drug candidate - Investing.com UK
Nurix Therapeutics Deal With Roche Is Worth Betting On (NASDAQ:NRIX) - Seeking Alpha
Nurix Highlights Promising Phase 1b Data for Bexobrutideg - TipRanks
Nurix Therapeutics reports Phase 1a/1b update: 83% ORR, 22.1-month median PFS; 600 mg RP2D well tolerated - TradingView
Nurix (NASDAQ: NRIX) shows high CLL response rates in bexobrutideg Phase 1 - Stock Titan
Nurix Therapeutics To Report Updated Phase 1A/B Results For Btk Degrader Bexobrutideg, Highlighting Durable Responses In Relapsed/Refractory Cll/Sll And Promising Activity In Earlier Lines Of Therapy - TradingView
Experimental BTK degrader sees 83% response in relapsed CLL - Stock Titan
How Roche’s US$700 Million Bexobrutideg Alliance Will Impact Nurix Therapeutics (NRIX) Investors - Sahm
NRIX Reiterates Buy Rating by HC Wainwright & Co. -- Price Targe - GuruFocus
Nurix Therapeutics' (NRIX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Amova Asset Management Americas Inc. Has $24.48 Million Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
NRIX Maintained by Truist Securities -- Price Target Raised to $32 - GuruFocus
Nurix Therapeutics Inc. (NRIX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Sahm
NRIX Maintained by BTIG -- Price Target Raised to $32 - GuruFocus
Nurix Therapeutics Inc (NRIX) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):